The future is bright for oncology, given that 1,600 drugs and vaccines for a wide variety of malignancies are in development, speakers noted during AMCP Nexus 2024, in Las Vegas. Nearly 75% of newly initiated trials in 2023 were for rare cancers, and 82% were of potential treatments for solid tumors, the speakers told attendees.
“This is an exciting time for oncology therapeutics,” said Kaelyn Boss, PharmD, a clinical consultant pharmacist at the University of